UBS AM’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.5M | Buy |
243,373
+34,617
| +17% | +$1.91M | ﹤0.01% | 1213 |
|
|
2025
Q1 | $10.1M | Sell |
208,756
-79,155
| -27% | -$3.83M | ﹤0.01% | 1222 |
|
|
2024
Q4 | $11.1M | Sell |
287,911
-80,221
| -22% | -$3.1M | ﹤0.01% | 1199 |
|
|
2024
Q3 | $16.6M | Sell |
368,132
-1,823
| -0.5% | -$82K | ﹤0.01% | 1024 |
|
|
2024
Q2 | $12.8M | Buy |
369,955
+34,637
| +10% | +$1.2M | ﹤0.01% | 1035 |
|
|
2024
Q1 | $9.7M | Buy |
335,318
+46,239
| +16% | +$1.34M | ﹤0.01% | 1013 |
|
|
2023
Q4 | $6.63M | Buy |
289,079
+218,020
| +307% | +$5M | ﹤0.01% | 1141 |
|
|
2023
Q3 | $1.19M | Buy |
71,059
+6,281
| +10% | +$105K | ﹤0.01% | 1867 |
|
|
2023
Q2 | $1.49M | Hold |
64,778
| – | – | ﹤0.01% | 1817 |
|
|
2023
Q1 | $1.49M | Buy |
+64,778
| New | +$1.49M | ﹤0.01% | 1817 |
|
|
2022
Q4 | – | Sell |
-27,275
| Closed | -$230K | – | 2710 |
|
|
2022
Q3 | $230K | Sell |
27,275
-5,389
| -16% | -$45.4K | ﹤0.01% | 2563 |
|
|
2022
Q2 | $258K | Hold |
32,664
| – | – | ﹤0.01% | 2513 |
|
|
2022
Q1 | $773K | Hold |
32,664
| – | – | ﹤0.01% | 2269 |
|
|
2021
Q4 | $1.12M | Buy |
32,664
+5,066
| +18% | +$173K | ﹤0.01% | 2153 |
|
|
2021
Q3 | $489K | Hold |
27,598
| – | – | ﹤0.01% | 2511 |
|
|
2021
Q2 | $1.24M | Buy |
27,598
+2,598
| +10% | +$117K | ﹤0.01% | 2095 |
|
|
2021
Q1 | $648K | Buy |
25,000
+12,800
| +105% | +$332K | ﹤0.01% | 2292 |
|
|
2020
Q4 | $246K | Buy |
+12,200
| New | +$246K | ﹤0.01% | 2458 |
|